U.S. Stock Movement | DBV Technologies Surges Over 30% Pre-Market Following Positive Phase III Trial Results for Peanut Allergy Patch in Children Aged 4-7
Gelonghui December 17 | DBV Technologies surged more than 30% in pre-market trading. This follows the announcement by DBV Technologies of positive preliminary results from the Phase 3 VITESSE trial of the VIASKIN peanut patch in 4-7-year-old children with peanut allergies, which met its primary endpoint. The BLA submission for 4-7-year-olds is scheduled to occur in the first half of 2026.
Gelonghui FinanceDec 17, 2025 17:16